<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05073913</url>
  </required_header>
  <id_info>
    <org_study_id>APHP191038</org_study_id>
    <secondary_id>IDRCB 2020-A00723-36</secondary_id>
    <nct_id>NCT05073913</nct_id>
  </id_info>
  <brief_title>Vascular Remodeling After Living Kidney Donation Study</brief_title>
  <acronym>EUGENIA</acronym>
  <official_title>Vascular Remodeling After Living Kidney Donation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Vascular evaluation of candidates to living kidney donation is important because there is an&#xD;
      increased risk of end stage renal disease and cardiovascular disease after donation. The&#xD;
      implication of vascular remodeling in the vascular morbidity observed in donors has not been&#xD;
      established because the parameters of vascular remodeling in donors have so far been poorly&#xD;
      described. The object of the present study is to study the evolution of vascular remodeling&#xD;
      of small, medium and large vessels (until then not evaluable by standard techniques) before&#xD;
      and one year after living kidney donation, by dedicated-, non invasive-examinations, which&#xD;
      results are associated with cardiovascular risk in the general population. This approach will&#xD;
      make it possible to precisely assess the impact of unilateral nephrectomy on vascular&#xD;
      remodeling after living donation and to estimate the change in cardiovascular risk&#xD;
      attributable to the donation. These results will also help refine the assessment of&#xD;
      candidates for kidney donation and potentially open up new strategies to improve selection&#xD;
      process of candidates to living kidney donation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 2021</start_date>
  <completion_date type="Anticipated">September 2025</completion_date>
  <primary_completion_date type="Anticipated">September 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Carotid artery rigidity</measure>
    <time_frame>1 year after living kidney donation</time_frame>
    <description>Carotid stiffness, as measured by echotracking</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Measured glomerular filtration rate</measure>
    <time_frame>1 year after living kidney donation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulse wave velocity</measure>
    <time_frame>1 year after living kidney donation</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Endothelial function</measure>
    <time_frame>1 year after living kidney donation</time_frame>
    <description>Measured Glomerular Filtration Rate (urinary clearance of 99mTc-DTPA) unit: ml/min/1,73 m²</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Small arteries remodeling</measure>
    <time_frame>1 year after living kidney donation</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Living Kidney Donation</condition>
  <arm_group>
    <arm_group_label>Living kidney donors</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>complete vascular exploration before and one year after nephrectomy</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Vascular remodeling characterization</intervention_name>
    <description>Pulse wave velocity measure High frequency ultrasonography for vascular imaging Endothelial function test Left ventricular mass by echocardiography Measurement of GFR (Glomerular Filtration Rate) with 99mTc DTPA</description>
    <arm_group_label>Living kidney donors</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  candidate to living kidney donation&#xD;
&#xD;
          -  affiliated to national health insurance&#xD;
&#xD;
          -  capable of understanding the consequences of participating to the study&#xD;
&#xD;
          -  written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  contraindication to living kidney donation&#xD;
&#xD;
          -  pregnancy&#xD;
&#xD;
          -  breastfeeding&#xD;
&#xD;
          -  allergy to echographic gel, allergy to cutaneous dressings&#xD;
&#xD;
          -  cutaneous lesions preventing the ultrasonography probe to be applied on the skin&#xD;
&#xD;
          -  participation to a drug trial&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marie COURBEBAISSE, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>marie.courbebaisse@aphp.fr</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Marie COURBEBAISSE, MD, PhD</last_name>
    <phone>+33 1 56 09 39 69</phone>
    <email>marie.courbebaisse@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Natacha NOHILE</last_name>
    <phone>+33 1 56 09 59 82</phone>
    <email>natacha.nohile@aphp.fr</email>
  </overall_contact_backup>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 10, 2021</study_first_submitted>
  <study_first_submitted_qc>October 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 12, 2021</study_first_posted>
  <last_update_submitted>October 11, 2021</last_update_submitted>
  <last_update_submitted_qc>October 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>living kidney donors</keyword>
  <keyword>endothelial function</keyword>
  <keyword>vascular remodeling</keyword>
  <keyword>pulse wave velocity</keyword>
  <keyword>glomerular filtration rate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vascular Remodeling</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Individual participant data (IPD) that underlie results in publication could be shared. IPD detailed in the protocol of a planned metaanalysis could be shared</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>Two years after the last publication</ipd_time_frame>
    <ipd_access_criteria>Data sharing must be accepted by the sponsor and the PI based on scientific project and scientific involvement of the PI team. Collaboration will be fostered. The founder could be involved in the decision.&#xD;
Data sharing must respect the agreements made with funders. Teams wishing obtain IPD must meet the sponsor and IP team to present scientific (and commercial) purpose, IPD needed, format of data transmission, and timeframe. Technical feasibility and financial support will be discussed before mandatory contractual agreement. contractualization.&#xD;
Processing of shared data must comply with European General Data Protection Regulation (GDPR).</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

